UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005312
Receipt number R000006307
Scientific Title A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.
Date of disclosure of the study information 2011/03/25
Last modified on 2014/02/25 00:10:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.

Acronym

A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.

Scientific Title

A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.

Scientific Title:Acronym

A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.

Region

Japan


Condition

Condition

Osteosarcoma
Soft tissue sarcoma
neuroblastoma






























































































































































































Pediatric bone, soft tissue sarcoma at high risk of recurrence.

Classification by specialty

Hematology and clinical oncology Pediatrics Child

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to evaluate the efficacy of WT1 peptide vaccination for pediatric malignant patients after conventional chemotherapy.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase I,II


Assessment

Primary outcomes

Time to progression from the end of conventional chemotherapy.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Vaccine

Interventions/Control_1

See Japanese protocol or ask directly to us.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

0 years-old <

Age-upper limit

20 years-old >

Gender

Male and Female

Key inclusion criteria

See Japanese protocol or ask directly to us.

Key exclusion criteria

See Japanese protocol or ask directly to us.

Target sample size

22


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshikio Hashii

Organization

Osaka University

Division name

Pediatrics

Zip code


Address

2-2, Yamadaoka Suita

TEL

06-6879-3932

Email

areken@ped.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yoshiko Hashii

Organization

Osaka univ

Division name

Pediatrics

Zip code


Address

2-2, Yamadaoka Suita

TEL

06-6879-3932

Homepage URL


Email

areken@ped.med.osaka-us.jp


Sponsor or person

Institute

Osaka Universty

Institute

Department

Personal name



Funding Source

Organization

Osaka University

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪大学医学部付属病院


Other administrative information

Date of disclosure of the study information

2011 Year 03 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2010 Year 10 Month 20 Day

Date of IRB


Anticipated trial start date

2010 Year 11 Month 01 Day

Last follow-up date

2015 Year 09 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 03 Month 25 Day

Last modified on

2014 Year 02 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006307


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name